MZE829 An oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, designed from protective human genetic variants.
Visit productCosigns Received
Be the first Cosign
Put your name behind MZE829.
Add it to your Products I use list and share why you use it.